Search

Displaying results 4231 - 4240 of 5449 in total
  1. Drug

    mRNA-3705

    go.drugbank.com/drugs/DB17668
    Investigational

    Developed by Moderna TX Inc., it is being investigated for the treatment of methylmalonic academia.[A258843]

  2. Drug

    RLYB212

    go.drugbank.com/drugs/DB17727
    Investigational

    It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.

  3. Drug

    SAR-439459

    go.drugbank.com/drugs/DB17864
    Investigational

    [A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.

  4. Drug

    Efdoralprin alfa

    go.drugbank.com/drugs/DB18384
    Investigational

    [L54928] It is being investigated as a restorative therapy in adults with AATD emphysema.[L54928]

  5. Drug

    AB-201

    go.drugbank.com/drugs/DB18629
    Investigational

    [L48340] It is under investigation for the treatment of HER2-positive cancers, including breast and gastric carcinomas.

    Synonyms: Ex vivo expanded allogeneic cord blood-derived NK cells that have been genetically modified to express a HER2-directed CAR and secrete IL-15
  6. Drug

    OTL-203

    go.drugbank.com/drugs/DB18643
    Investigational

    OTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.

    Synonyms: Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene
  7. Drug

    THR-184

    go.drugbank.com/drugs/DB19097
    Investigational

    THR-184 is under investigation in clinical trial NCT01830920 (A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-acute Kidney Injury (CSA-AKI)).

  8. Drug

    BRD-810

    go.drugbank.com/drugs/DB23607
    Experimental

    It is an inhibitor of the protein myeloid cell leukemia 1 (MCL1). [A274263]

  9. Drug

    Iodide I-123

    go.drugbank.com/drugs/DB09420
    ApprovedInvestigational

    Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared

  10. Drug

    Imetelstat

    go.drugbank.com/drugs/DB14909
    ApprovedInvestigational

    [A263973] It is used to treat anemia in patients with myelodysplastic syndromes (MDS), a group of hematologic disorders characterized by ineffective hematopoiesis, peripheral cytopenia, abnormal marrow